TEE crtcat Reviews i Oneologyttematotogy = Elderty patients with advanced colorectal cancer derive Similar benefit without excessive tonicity after firstline chemotherapy with oxaliplatin-based combinations. Comparative outcomes from the 03-TTD-01 phase III study ites //soh ora 1076. ervevone 2008.1) 002 ‘Sotoghte and canton Abstract Purpose Healthy elderly patiants with metastatic colorectal cancer may banefitfrom chemotherapy 92 muchas the younger Rapiilation. This enalysis compares the outcomes of firseline: oxalipistn plus toropyrimicines in eider'y versus young patients Patients and methods 348 pationts were randomized to capecitabine 1000 mgl(r? 12 h), days 14 plus oxaliplatn 130 mpm? day 1, every 5 weeks or weekiy infusional 5-FU 2250 maim? over 48 h plus bimonthly oxaliplztn @5 malm?. We evaluated response rate, time to progression, overall survval and toxicity according to age Results ORR tor elderly and youna pationts were 24.9% and 44.7% respectively (2 = 0.087) Modian TTP did not afer between the two groups: 6.3 months for patients 270 yoars and 9.6 months for those <70 years (o 114). Median OS was 16.8 months and 20.5 months for tha 270 and «70 yoars grouns, rospoctivaty (9 = 0.74). With XELOX, rid paresthesia and an increase in transaminase levels were rors frequent for yourg patients, whereas grade 3/4 diarrhea was higher in those 270 years (25% vs. 8%, p = 0.008), For FUOX, only paresthesia was significantly lawer in patients 270 yoars (52% vs. 71%, 0 = 0.022). ‘Conehusion Elderly patients with MCRC benefit rom firstline oxalipletinfuoropynmidine combinations as rnuch as younger patients, without increased toxicity Keywords Capecitabine: Cxaliglatin, 5-FU: Metastatic colorectal cancer, Elderly patientsIrinotecan, leucovorin and 5-fluorouracil (modified FOLFIRI) as salvage chemotherapy for frail or elderly patients with advanced gastric cancer Authors: © Jung Han Sinn, Hygong Su Kim, A Rum Han, In Ho Moh, Doo Cheol Chung, Dae Ro Choi, Hyun Joo lang, Jin Bae Kim, Dae Hyun Yang, Soon it Lee, Dae Young Zang View Affiliations Published online on: July 2, 2012 hltps /fechorg/10.u9z/ol.2072.782 Pagess75)-754 Abstract We retraspectively evaluated the efficacy and safety of the madified FOLFIRI regirnen in frail ar elderly patients with advanced gastric cancer {AGC]. We reviewed 24 frail [Eastern Cooperative Oncology Group performance siaius (ECOG PS) of 2] or elderty (65 years or over) patisnts with AGC who received the modified FOLFIRI regimen as salvage chemotherapy. Patients received irinatecan 180 me/m? and leucovorin (LVI 409 mg/m? as a? h intravenous infusion, follawed by 5-flusrouracil (5-FU) 2,000 ma/m2 as 246 h continuous infusion. Amang the 24 patients, 18 175%] had an ECOG PS of 2, and 1 (45.8%) were aged 65 yeers or over: A total of 113 cycles were conducted, with a inedian number af 4 cycles per patient. A total of 3 patients achieved partial respanse (PR) and 8 demonstrated stable disease (SD). On an intent-to-treat basis, the averall response rate (RRI wes 12.5% and the disease control rate [PR and SD] wes 45.8%. The median time to progression (TT?] was 2 months 195% confidence interval (Ci). 4,9-2.1 manthsl and the median averall survival (OS] was 5.4 manths (95% Cl, 4.16.7 months). Grade 3-4 hematological toxicities, including neutrapenia, anemia and thrombocytepenia, were observed in 6 (25%), 4 [16.7%] and 1 (4.2%) patients, respectively. Additionally, 3 [12.5%] patients developed febrile neutropenia, of which | succumbed 16 pneumonia. Grade 3-4 gasiraintestinal toxicities, including nausea, vomiting, diarrhea and mucositis, were observed in 3 (12.5%), 2 (8.3%), 1 (4.2%) and (4.2%) patients, respectively. In conclusion, the modified FOLFIRI regimen as salvage chemotherapy for AGC patienis over 65 years of age or with @ poor PS was effective and acceptable, These results suggest that this regimen may be an effective option for frail or elderly patients with AGC.